The average one-year price target for Roivant Sciences (NASDAQ:ROIV) has been revised to 15.81 / share. This is an increase of 10.71% from the prior estimate of 14.28 dated June 1, 2023.
The price target is an average of many targets provided by analysts. The latest targets range from a low of 11.11 to a high of 24.15 / share. The average price target represents an increase of 48.73% from the latest reported closing price of 10.63 / share.
What is the Fund Sentiment?
There are 192 funds or institutions reporting positions in Roivant Sciences. This is an increase of 42 owner(s) or 28.00% in the last quarter. Average portfolio weight of all funds dedicated to ROIV is 1.48%, a decrease of 23.34%. Total shares owned by institutions increased in the last three months by 11.40% to 475,134K shares. 
The put/call ratio of ROIV is 0.18, indicating a bullish outlook.
What are Other Shareholders Doing?
QVT Financial holds 122,542K shares representing 16.16% ownership of the company. No change in the last quarter.
Viking Global Investors holds 88,239K shares representing 11.63% ownership of the company. No change in the last quarter.
Sb Investment Advisers holds 83,032K shares representing 10.95% ownership of the company. In it's prior filing, the firm reported owning 95,032K shares, representing a decrease of 14.45%. The firm decreased its portfolio allocation in ROIV by 20.49% over the last quarter.
Adage Capital Partners Gp, L.l.c. holds 14,881K shares representing 1.96% ownership of the company. In it's prior filing, the firm reported owning 8,998K shares, representing an increase of 39.53%. The firm increased its portfolio allocation in ROIV by 43.22% over the last quarter.
Wellington Management Group Llp holds 12,029K shares representing 1.59% ownership of the company.
Roivant Sciences Background Information
(This description is provided by the company.)
Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch "Vants" - nimble and focused biopharmaceutical and health technology companies
Additional reading:
- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
- ROIVANT SCIENCES LTD. EMPLOYEE STOCK PURCHASE PLAN (as amended on March 27, 2023)
- Roivant Sciences Ltd. Stock Option Grant Notice (Amended and Restated 2015 Equity Incentive Plan)
- Roivant Sciences Ltd. Restricted Stock Unit Award Grant Notice (2015 Equity Incentive Plan)
- ROIVANT SCIENCES LTD. 2015 EQUITY INCENTIVE PLAN PERFORMANCE OPTION GRANT NOTICE
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
